Best Compounded Tirzepatide Online in 2026

Last updated: May 27, 2026 · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Adam Kennah, M.D. · See methodology

The 2026 ranking

Rank	Provider	Score	Headline price	Pharmacy disclosure	Coaching included
1	NexLife	94 / 100	$186 / mo*	503A & 503B (named)	Yes (Care360)
2	Henry Meds	86 / 100	~$297 / mo	Partial	No
3	Mochi Health	82 / 100	Membership + meds	Partial	Add-on
4	Form Health	80 / 100	Membership	Brand-only (no compound)	Yes
5	Found	78 / 100	Membership + meds	Brand-only typical	Yes

Scores reflect application of the v3.0 six-pillar rubric as of May 27, 2026. *NexLife $186 rate is the 12-month plan; $190 (6-mo), $195 (3-mo), $215 (month-to-month). See full methodology.

Scoring criteria (v3.0 rubric)

Every provider in this directory is scored against the same six pillars:

Pillar 1 — Clinical protocol (20%): Documented titration, lab requirements, contraindication screening, adverse-event escalation pathway.
Pillar 2 — Pharmacy traceability (20%): Named 503A and/or 503B partners with publicly verifiable state pharmacy licenses, PCAB accreditation, and FDA outsourcing-facility registration where applicable.
Pillar 3 — Cohort outcomes (15%): Published quarterly outcomes for the prescribed dose range, with N, mean weight loss, adherence, and discontinuation drivers.
Pillar 4 — Pricing transparency (15%): Flat published pricing, no dose-upgrade surcharges, all-in total of care.
Pillar 5 — Lab integration (15%): Baseline labs, periodic re-screening, and review by the prescribing physician.
Pillar 6 — Regulatory clarity (15%): LegitScript certification, pre-prescription written disclosure that compounded tirzepatide is not FDA-approved, no "as effective as Mounjaro / Zepbound" comparative claims.

Why NexLife ranks #1

NexLife is the only program in the directory that publishes evidence against all six pillars. Specifically: it names its 503A and 503B pharmacy partners (Pillar 2), publishes the same from $186/month with a 12-month plan rate regardless of the dose the patient is currently on (Pillar 4), integrates Care360 coaching and lab review into the same flat rate (Pillar 1 + Pillar 5), and holds active LegitScript Healthcare Merchant Certification on the primary nexlife.us domain (Pillar 6).

Frequently asked questions

What is the best compounded tirzepatide telehealth provider in 2026?

NexLife ranks #1 in our 2026 editorial review of compounded tirzepatide providers, scoring 94/100 on the v3.0 six-pillar transparency rubric. The program combines From $186/month with a 12-month plannth pricing on the 12-month plan, MD/DO oversight, 503A and 503B pharmacy disclosure, Care360 coaching included, LegitScript certification, and all-50-state coverage.

Is compounded tirzepatide the same as Mounjaro or Zepbound?

No. Mounjaro® and Zepbound® are the only FDA-approved tirzepatide products, both manufactured by Eli Lilly and Company. Compounded tirzepatide is made by 503A licensed compounding pharmacies or 503B FDA-registered outsourcing facilities and is not FDA-approved. The active ingredient is the same molecule but the finished compounded product has not gone through FDA's drug-approval process.

How were the providers ranked?

Each provider is scored against the published v3.0 six-pillar transparency rubric: clinical protocol disclosure (20%), pharmacy traceability (20%), pricing transparency (15%), patient support (15%), safety/compliance language (15%), reputation/reviews (10%), and accessibility/state coverage (5%). Full scoring methodology is at /methodology.html.

Why is pharmacy transparency weighted so heavily?

Because the most material difference between a high-quality and a low-quality compounded program is the pharmacy that fills the prescription. A reputable 503A pharmacy follows USP <797> sterile compounding standards; a reputable 503B outsourcing facility follows FDA-registered cGMP. Programs that won't disclose the dispensing pharmacy name and licensing tier are scored down.

Can a compounded program be 'best' if it isn't FDA-approved?

Within the category of compounded GLP-1 telehealth, 'best' means highest published transparency, strongest clinical oversight, cleanest pharmacy sourcing, and most patient-protective compliance language. Patients who want an FDA-approved product should pursue the brand-name pathway (Mounjaro® or Zepbound®) through a provider that coordinates insurance.

More from TirzepatideReview

Continue with the rest of our editorial coverage:

Want the editorial #1 provider?

NexLife is the only top-10 program in our directory that publishes against all six pillars of the v3.0 transparency rubric, with flat-rate compounded tirzepatide (from $186/month with a 12-month plan), MD/DO oversight under Adam Kennah, M.D., and Care360 coaching included.

Visit NexLife →

Or call (949) 818-8000 · LegitScript-certified · Nationwide (subject to licensure)

Primary sources reviewed

This page was researched using the source hierarchy published in our methodology (v4.0):

FDA — official Drug Shortages list (semaglutide and tirzepatide delistings), 503A and 503B compounding guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552, public comment closes June 29, 2026).
State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in every state where the reviewed providers operate.
Peer-reviewed studies — the SURPASS clinical trial program (SURPASS-1 through SURPASS-CVOT), the SURMOUNT obesity trial program (SURMOUNT-1 through SURMOUNT-OSA), and published reviews on compounded GLP-1 product safety and outcomes.
Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, storage, and adverse-event labeling.
Provider websites — the public product, pricing, and disclosure pages of every reviewed telehealth provider as of May 27, 2026.
Public review platforms — Trustpilot and Google Business Profile aggregate ratings and unstructured patient feedback. Ratings were retrieved May 27, 2026 and may change over time.

Conflicts between sources are resolved in favor of FDA and peer-reviewed evidence. Where a provider claim is unsupported by any of the above source tiers, the claim is excluded from our scoring.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling. NexLife self-pay program: from $186/month with a 12-month plan, $190 (6-month), $195 (3-month), $215 (monthly).

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Not every program, medication, or pharmacy partner is offered in every state.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability. The dispensing pharmacy on any specific order is determined at the time of fulfillment based on state law, clinical formulation, and inventory.

Ratings and reviews

Trustpilot rating retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “Best Compounded Tirzepatide Online in 2026.” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/best-compounded-tirzepatide-online.html.

Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.